News
Repare Therapeutics Inc. (RPTX) maintained a gain of over 20%, reaching a high of $2.66, a new intraday high in the past year. The cancer drug development company announced the sale of its polymerase ATPase inhibitor RP-3467 to Gilead Sciences, with a transaction amount of up to $30 million
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments